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Haemophilus ducreyi is the etiologic agent of the sexually transmitted genital ulcer disease chancroid. Neither
naturally occurring chancroid nor experimental infection with H. ducreyi results in protective immunity.
Likewise, a single inoculation of H. ducreyi does not protect pigs against subsequent infection. Accordingly, we
used the swine model of chancroid infection to examine the impact of multiple inoculations on a host’s immune
response. After three successive inoculations with H. ducreyi, pigs developed a modestly protective immune
response evidenced by the decreased recovery of viable bacteria from lesions. All lesions biopsied 2 days after
the first and second inoculations contained viable H. ducreyi cells, yet only 55% of the lesions biopsied 2 days
after the third inoculation did. Nearly 90% of the lesions biopsied 7 days after the first inoculation contained
viable H. ducreyi cells, but this percentage dropped to only 16% after the third inoculation. Between the first
and third inoculations, the average recovery of CFU from lesions decreased approximately 100-fold. The
reduced recovery of bacteria corresponded directly with a fivefold increase in H. ducreyi-specific antibody titers
and the emergence of bactericidal activity. These immune sera were protective when administered to naïve pigs
prior to challenge with H. ducreyi. These data suggest that pigs mount an effective humoral immune response
to H. ducreyi after multiple exposures to the organism.
Chancroid is a sexually transmitted infection often seen in
resource-poor tropical areas (34) and is a prevalent genital
ulcer disease in certain areas of Asia, Africa, and Latin Amer-
ica (31, 34, 35). As both cross-sectional cohort studies and
prospective longitudinal studies indicate that all genital ulcer
disease (13, 23, 41, 51) and chancroid in particular (31, 33)
increase the risk for sexual transmission and acquisition of
human immunodeficiency virus type 1 (HIV-1), control of
chancroid could provide an effective intervention strategy
against the spread of human immunodeficiency virus type 1
(18, 21, 27, 34, 37, 41, 44, 52). Control of chancroid is compli-
cated by the fact that natural chancroid infection does not
appear to protect against subsequent infection (6, 25, 43).
Concordantly, a single experimental infection with Haemophi-
lus ducreyi does not protect human volunteers against subse-
quent experimental challenge (4, 49).
Humans mount what appears to be a delayed-type (type IV)
hypersensitivity reaction in response to H. ducreyi (22, 32, 38,
49). This response is neither protective against future infection
nor effective at clearing chancroid infections as lesions can
persist for weeks or months and ulcer resolution is often in-
complete in the absence of antibiotic therapy (34). One possi-
ble reason for the ineffective nature of this response is that
cell-mediated immunity is highly effective at killing intracellu-
lar bacteria and viruses (30), yet the majority of H. ducreyi
present in chancroid lesions are extracellular (5).
While the delayed-type (type IV) hypersensitivity response
appears ineffective at preventing future chancroid infections, it
is unclear what sort of response would be protective. The
extracellular existence of the bacteria suggests that a humoral
immune response could be protective against infection. We
repeatedly exposed pigs to H. ducreyi in an attempt to elicit and
identify a protective immune response in the swine model of
chancroid. Pigs, like humans, are not protected from subse-
quent infection by a single exposure to H. ducreyi. However,
after three inoculations at 14-day intervals, pigs developed a
modest but significant level of protective immunity against H.
ducreyi. Protection was defined not as an absolute block of
infection but rather as a reduction in disease severity as indi-
cated by reduced recovery of viable H. ducreyi cells. Passive
transfer of immune serum protected naïve animals against
challenge with H. ducreyi. These results from the swine model
support the idea that humoral immunity to H. ducreyi could
provide protection against infection by this organism.
MATERIALS AND METHODS
Bacterial inoculum preparation. The inoculum was prepared and quantified as
previously described (29, 45). Briefly, H. ducreyi strain 35000HP (gift from
Stanley Spinola) was grown from a freezer stock and passed once on chocolate
agar plates containing 1.5% (wt/vol) Bacto agar, 2.5% brain heart infusion
(BHI), 1% hemoglobin, 1% IsoVitaleX (all from Becton Dickinson, Cock-
eysville, Md.), 5% newborn calf serum, and 5% fetal bovine serum (Life Tech-
nologies, Inc., Rockville, Md.) at 35°C in a humidified incubator with 5% CO2.
Vancomycin, when used, was added to growth media at a concentration of 3
g/ml.
Animals. Juvenile female crossbred (Yorkshire-Landrace crossed with Hamp-
shire-Duroc [hereafter, Yorkshire cross]) pigs were employed as previously de-
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scribed (29). Pigs were housed in individual enclosures at North Carolina State
University College of Veterinary Medicine in a P2 containment facility accred-
ited by the American Association for Accreditation of Laboratory Animal Care.
All pigs were 6 weeks old at the beginning of the study. Animals were sedated for
procedures with 0.3 ml of a TKX cocktail per 22.7 kg of body weight. The cocktail
consisted of tiletamine HCl-zolazepam HCl (each, 50 mg/ml), (Telazol; Fort
Dodge Laboratories, Fort Dodge, Iowa), ketamine HCl (50 mg/ml) (Fort Dodge
Laboratories), and xylazine (50 mg/ml) (Miles Laboratories, Shawnee Mission,
Kans.). Atropine sulfate (Phoenix Scientific Inc., Joseph, Mo.) was given in the
amount of 0.5 ml to 1 ml, depending on the size of the animal, in order to slow
bronchial secretion and prevent aspiration.
Inoculation. Eight sites on the dorsal side of each ear for a total of 16 sites per
pig were inoculated with Multi-Test multiple skin test applicators (Lincoln Di-
agnostics, Decatur, Ill.) as previously described (29, 49). Two sites per ear were
inoculated with the Multi-Test applicators loaded with each of the following: 106
CFU of H. ducreyi 35000HP, 107 CFU of H. ducreyi 35000HP, 106 CFU of
heat-killed H. ducreyi 35000HP, or 10 l of sterile phosphate-buffered saline
(PBS). This inoculation scheme resulted in an estimated delivered dose of 4 
103 to 4  104 CFU to the dermis and epidermis of the skin (46). Inoculations
were repeated at 14-day intervals (Fig. 1). Inoculations were carefully placed
such that no two successive sites overlapped. In addition to the pigs that received
all three inoculations, one pig received no inoculations, and two pigs received
only the first inoculation.
Biopsy of samples. Inoculation sites were excised 2 or 7 days following each
inoculation with 6-mm-diameter skin punches (Acuderm, Ft. Lauderdale, Fla.).
Tissues were bisected with sterile scalpels (Acuderm). One half of each biopsy
was fixed in 4% paraformaldehyde in PBS, while the other half was minced and
plated on chocolate agar plates with 3 g of vancomycin per ml for recovery and
enumeration of viable H. ducreyi. If recovery plates were excessively contami-
nated, the recovery data were not included in our analyses. Fixed sample halves
were embedded in paraffin, sectioned, stained with hematoxylin and eosin (His-
topathology Reference Laboratory, Richmond, Calif.), and blindly scored for
histological severity according to our previously developed scoring system (46)
(data not shown).
Sera and complement collection. Sera were collected weekly from all animals.
One of the animals receiving a single inoculation suffered a leg injury and was
euthanized prior to the completion of the study. This animal had serum collected
for the final time on day 42 instead of day 49.
Collected blood was allowed to clot overnight at 4°C. Blood was centrifuged at
room temperature in a bench top centrifuge at 408  g for 10 min prior to the
removal of serum. Serum was centrifuged again at room temperature in a bench
top centrifuge at 408  g for 10 min before aliquots were frozen at 80°C.
Pig complement was collected from separate naïve Yorkshire cross pigs. Blood
was drawn from animals and clotted at 37°C for 30 min. Serum was removed and
centrifuged at 4°C at 2,000  g for 10 min. Serum was passed through a 0.45-m
syringe filter, aliquoted, and frozen immediately at 80°C. Aliquots were used
only once as an active complement source.
Immune bactericidal assays. H. ducreyi 35000HP was grown for 16.5 h from a
freezer stock on chocolate agar at 35°C with 5% CO2. Cells were harvested and
suspended in 2 ml of BHI broth (Becton Dickinson, Cockeysville, Md.). Cells
were vortexed for 5 s and allowed to settle for 5 min in order to remove large
aggregates of H. ducreyi. After settling, the top 1 ml of the bacterial solution was
removed and the cell density was adjusted such that the final concentration of
bacteria was 100 to 500 CFU per 80 l of media.
Bactericidal assays were performed as described (15, 16). Briefly, assays were
performed in sterile 96-well plates (Falcon microtest tissue culture plate; Becton
Dickinson, Franklin Lakes, N.J.). Each test well received 80 l of cells and 10 l
(or 10%) of heat-inactivated test serum. Plates were incubated for 15 min at 35°C
with 5% CO2 after which 10 l (or 10%) of either heat-inactivated or active fresh
pig complement serum was added. Plates were mixed by tapping and then
incubated for an additional 45 min. Bacteria were quantified by plating 60 l
from each well onto chocolate agar. Percent survival was determined for each
immune serum sample tested by dividing the number of colonies that survived
exposure to fresh serum complement by the number of colonies that survived
with heat-inactivated serum complement and multiplying by 100. To ensure that
the serum complement did not kill the bacteria in an antibody-independent
fashion, we used BHI media in place of the serum antibody source in bactericidal
assays. The average percent survival in the BHI medium was consistently greater
than 100% (data not shown), indicating that complement containing serum, in
the absence of antibody, did not kill the bacteria. Samples were assayed in
triplicate on three separate days.
Serum IgG determination. Total serum immunoglobulin G (IgG) was mea-
sured following the manufacturer’s protocol with a pig serum IgG enzyme-linked
immunosorbent assay (ELISA) kit (Bethyl Laboratories, Montgomery, Tex.). H.
ducreyi-specific IgG was measured by a similar method; however, instead of
coating microplate wells (96-well MaxiSorp; Nalge Nunc, Rochester, N.Y.) with
goat anti-pig IgG capture monoclonal antibody, wells were coated with whole-
cell H. ducreyi lysate at a concentration of 10 g/ml in 100 mM sodium carbonate,
pH 9.6. The lysate was made by sonicating plate-grown H. ducreyi 35000HP on
ice in a mixture of 50 mM sodium phosphate (monobasic) and 300 mM sodium
chloride, pH 7.8. Insoluble particles and unbroken whole cells were removed
from the sonicate mixture by centrifugation at 800  g for 5 min. The sonicate
was filtered (pore size, 0.2 m) and assayed for total protein content (DC protein
assay; Bio-Rad Laboratories, Hercules, Calif.). Aside from the coating, both
ELISA formats were performed identically and in tandem. Coated wells were
blocked with 1% bovine serum albumin in Tris-buffered saline (50 mM Tris, 0.15
M sodium chloride, pH 8), then washed with TBST (Tris-buffered saline plus
0.05% Tween 20). Sera were serially diluted twofold in TBST containing 1%
bovine serum albumin, and a calibrator serum included with the ELISA kit was
run to assess the performance of each assay. Sera were incubated in the coated
plates and washed with TBST before being incubated with a goat anti-pig IgG
secondary antibody conjugated to horseradish peroxidase. After sera were
washed again with TBST, tetramethyl benzidine detection substrate (KPL,
Gaithersburg, Md.) was added to each well, allowed to develop, and stopped by
the addition of 2 M H2SO4. The optical density at 450 nm (OD450) was measured
with a SpectraMax 340PC microplate spectrophotometer, and response curves
were calculated with SOFTmax PRO software (Molecular Devices, Sunnyvale,
Calif.) This software was also used to perform four-parameter curve fitting for
the data. Titers were calculated by solving the four-parameter equation at an
OD450 value of 15 times the assay background. The assay background was
defined as the mean OD450 of all assay blank wells (containing all reagents except
serum), plus three times the standard deviation. Response curves for general
visual comparison were graphed with Microsoft Excel.
Passive transfer. Pigs were infused with 25 ml of serum with a 30-ml syringe
(Becton Dickinson, Franklin Lakes, N.J.) attached to a 6-in. male luer lock
adapter extension set (Baxter Healthcare Corporation, Deerfield, Ill.) and an
18-gauge needle (Becton Dickinson, Franklin Lakes, N.J.). Two pigs were in-
fused with normal pig serum, and five pigs were infused with serum from a
repeatedly inoculated pig. One day after infusion, pigs were inoculated according
to the procedure described above. Each pig was inoculated with live bacteria at
FIG. 1. Timeline of repeat inoculation study with Yorkshire cross pigs. Inoculations occurred at 14-day intervals. The ears of the pigs were
inoculated with live H. ducreyi at four sites per ear per inoculation. Lesion biopsies were collected either 2 or 7 days after each inoculation. Five
pigs were inoculated three times, two pigs were inoculated once, and one pig was never inoculated. Serum was collected from all pigs on a weekly
basis.
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eight sites per ear, for a total of sixteen live inoculations, and the entire biopsy
of each lesion was minced and plated for recovery. Day 7 recovery data from one
pig infused with bactericidal serum were not included in the Results section due
to overwhelming bacterial and fungal contamination on the recovery plates.
Statistical methods. Statistical analysis was performed with Sigma Stat version
2.0 (Jandel Scientific, San Rafael, Calif.) and SAS software (SAS Institute Inc.,
Cary, North Carolina). Bacterial recovery counts were modeled with gamma
regression modeling as a function of the day of the biopsy, and generalized
estimation equations were used to adjust the data for random effects. The
percentages of positive biopsies were analyzed via logistic regression analysis.
This hierarchical model was used to accommodate the effect of collecting mul-
tiple biopsies from single animals. Data analysis with t tests was used to compare
two groups for bactericidal assays, H. ducreyi-specific IgG titers, and recovery
data from serum-infused animals.
RESULTS
Recovery of viable bacteria decreased with repeated expo-
sure to H. ducreyi. Five pigs were inoculated with H. ducreyi
three times at 2-week intervals (Fig. 1). Two and seven days
following each inoculation, punch biopsies of inoculation sites
were collected and evaluated for lesion severity and recovery
of live H. ducreyi. Biopsy results from both inoculation dilu-
tions are presented together (Fig. 2), since analysis revealed
that percentages of culture-positive lesion biopsies were iden-
tical for all time points (data not shown). All biopsies collected
2 days following the first and second inoculations contained
live H. ducreyi, whereas only 55% of total biopsies taken 2 days
after the third inoculation were culture positive. We were sig-
nificantly more likely to recover bacteria from lesions biopsied
7 days after the first inoculation than after the third (89 versus
16% recovery; odds ratio, 45.33; 95% confidence interval, 4.89
to 420.48; P  0.0008) (Fig. 2).
The average number of bacteria recovered from culture-
positive lesions also dropped with repeated inoculations (Fig.
2). Gamma regression modeling revealed that significantly
more bacteria were recovered after the first versus the third
inoculation on both day 2 (odds ratio, 77.138; 95% confidence
interval, 14.86 to 400.41; P  0.0001) and day 7 (odds ratio,
310.00; 95% confidence interval, 61.30 to 1,567.75; P 
0.0001). Decreases in both the number of culture-positive
lesions and in CFU recovered per lesion suggest that after
three successive inoculations, pigs developed a modest but
significant level of protection against H. ducreyi infection.
H. ducreyi-specific serum IgG levels increased over the
course of multiple H. ducreyi inoculations. We measured total
and H. ducreyi-specific serum IgG levels at three time points,
preinoculation (day 0), 1 week after the second inoculation
(day 21), and 2 weeks after the final inoculation (day 42).
H. ducreyi-specific serum IgG titers were greater in the day
42 sera of pigs inoculated three times than in the day 21 or day
0 sera of the same animals (Table 1). Day 42 sera from these
pigs had 4.8-fold more H. ducreyi-specific IgG than sera col-
lected from the same animals prior to inoculation (Table 1) (P
 0.019, t test). To determine if the elevated antibody titers in
this group of pigs was due to multiple inoculations rather than
to an age-dependent effect, we evaluated serum from an ani-
mal that was inoculated once on day 0. While there was an
initial increase in H. ducreyi-specific IgG, this elevation did not
persist over the course of the experiment (Table 1). This result
FIG. 2. Percentage of all half-biopsies which were positive for recovery (A) and average recovery of CFU per half-biopsy (B). Data are from
five pigs inoculated three times at 14-day intervals. Four lesions from live H. ducreyi inoculations were collected from each animal 2 and 7 days
after each inoculation. CFU per half-biopsy were enumerated by mincing and plating half of each biopsy on chocolate agar. Recovery of one
bacterium was sufficient to mark the lesion biopsy as positive for recovery. (A) Fraction numerators are the number of lesion biopsies positive for
recovery, whereas denominators are the total number of lesion biopsies analyzed at that time point. Bars represent percentages of culture-positive
lesion biopsies. (B) Average CFU per half-biopsy was calculated for each time point by dividing the total CFU recovered by the number of biopsies
analyzed. This graph displays means and standard deviations.
TABLE 1. Summary of H. ducreyi-specific IgG titers from an
uninoculated pig and from pigs inoculated one and three times
Treatment (n)a
Titer1 (SD)
Day 0b Day 21c Day 42d
Three inoculations (4/5) 54 (3.2) 190 (1.8)e 260 (1.8)
One inoculation (1/2) 24 56 25
Uninoculated (1/1) 120 (1.1) 65 (1.0) 50 (1.0)
a n, number of pigs assayed/number of pigs treated.
b Day 0, preimmune serum.
c Day 21 serum was collected at the time corresponding to 1 week after the
second set of inoculations (See Fig. 1).
d Day 42 serum was collected 2 weeks after the time corresponding to the third
inoculation.
e Only two pigs were assayed at day 21.
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indicated that the increase in H. ducreyi-specific IgG resulted
from repeated exposure to H. ducreyi and not from a nonspe-
cific change in the pigs’ immune responses. There were no
appreciable changes in the levels of total IgG in these sera over
the course of the experiment (data not shown).
Serum from pigs inoculated multiple times displayed en-
hanced bactericidal activity against H. ducreyi. We used an
immune bactericidal assay to determine if the observed in-
creases in H. ducreyi-specific antibody titers corresponded with
increased bactericidal activity. We compared the bactericidal
activity of preimmune sera (day 0), sera collected 2 weeks after
the first inoculation (day 14), 2 weeks after the second inocu-
lation (day 28), and 3 weeks after the third inoculation (day 49)
(Fig. 1). We also tested sera collected from one uninoculated
pig and two pigs that received only one inoculation.
The average percent survival of H. ducreyi in preimmune
sera was 95%  35%, indicating that none of the preimmune
serum samples (n  8) exhibited bactericidal activity.
The average percent survival of H. ducreyi in day 14 sera of
animals receiving only one inoculation was 35%  32% (n 
7). The average percent survival of bacteria in day 28 sera from
twice-inoculated animals was 11%  17%. In sera drawn 3
weeks after the third and final inoculation, the average percent
survival of H. ducreyi was 23%  10% (Fig. 3). The average
percent survival of H. ducreyi in sera from the uninoculated pig
was approximately 100% regardless of the day the serum was
drawn (Fig. 3). This result indicated that emergence of bacte-
ricidal activity was not an age-related phenomenon.
We also wanted to determine if this enhanced bactericidal
activity resulted from just the first inoculation or was depen-
dent upon the multiple inoculation protocol. While day 14 sera
of animals receiving a single inoculation displayed enhanced
bactericidal activity, the average percent survival of H. ducreyi
in sera drawn 4 weeks after a single inoculation was 81  48%.
A similar 77  35% of bacteria survived in sera collected 7
weeks after a single inoculation (Fig. 3). In fact, sera drawn at
the end of the study from pigs that had received a single
inoculation did not exhibit a statistically significant difference
in bactericidal activity compared to activity in preimmune se-
rum. This finding suggested that while one inoculation with H.
ducreyi increased bactericidal antibody titers, this enhance-
ment was transient in the absence of repeated inoculations.
Day 49 sera from pigs inoculated three times had statistically
greater bactericidal activity than all preimmune sera (P 
0.001, t test). Day 49 sera from this group of pigs also had
much greater bactericidal activity than day 49 sera from ani-
mals that received one inoculation or that remained uninocu-
lated (Fig. 3). The increased bactericidal activity of sera col-
lected from the animals receiving three inoculations
corresponded with total H. ducreyi-specific IgG titers as mea-
sured by ELISA.
The passive transfer of bactericidal serum protected naïve
animals against H. ducreyi challenge. We hypothesized that
elevated titers of H. ducreyi-specific antibodies, possibly
through the action of complement-mediated killing, were pro-
viding the animals that received repeated inoculations with
protection against H. ducreyi challenge. To test this idea, we
transfused immune serum from a pig that received multiple
inoculations into naïve pigs before H. ducreyi challenge. As a
control, we also challenged naïve pigs infused with serum from
an uninoculated pig (normal pig serum). All lesions collected
from pigs infused with normal pig serum contained viable
bacteria. Two days after inoculation, 82.5% of the biopsies
collected from all immune serum-infused animals contained
viable bacteria. Seven days after inoculation, this percentage
dropped to 20%. Two of the pigs infused with immune serum
yielded exclusively sterile lesions on day 7. Only 25 and 43% of
day 7 lesions from the other two animals infused with immune
serum contained viable bacteria (Fig. 4). The difference in the
percentages of H. ducreyi-positive biopsies per pig for animals
infused with the immune versus normal pig serum was statis-
tically significant for day 7 biopsies (P  0.006, t test).
DISCUSSION
After three successive experimental chancroid infections,
pigs developed a modestly protective immune response against
H. ducreyi. The recovery of viable organisms from lesion biop-
sies as well as the number of culture-positive lesions decreased
throughout the experiment. This decreased recovery corre-
sponded directly with increased serum levels of H. ducreyi-
specific IgG and enhanced bactericidal activity. This finding
suggested that the humoral component of the immune re-
sponse was involved in mediating protection against H. ducreyi.
Because naïve pigs infused with serum from a pig that received
repeated inoculations were protected against H. ducreyi chal-
lenge, we concluded that the humoral component of the im-
mune response was playing a major role in mediating protec-
tion.
FIG. 3. Average percent survival of H. ducreyi in immune bacteri-
cidal assays with heat-inactivated pig sera collected after three, two,
one, or zero inoculations with H. ducreyi. Bars represent average per-
cent survival of H. ducreyi in sera drawn on the day indicated after
treatment described. The day 0 data bar represents survival of H.
ducreyi in sera drawn from all eight animals prior to any inoculations.
Day 14 data bars represent assays done with serum drawn from an
uninoculated animal and sera drawn from seven pigs that had received
one inoculation on day 0. Day 28 data bars represent assays done with
serum drawn from one uninoculated pig, sera drawn from two pigs that
received only one inoculation on day 0, and sera drawn from five pigs
that had received two prior inoculations on day 0 and day 14. Day 49
data bars represent the percent survival of H. ducreyi in sera drawn on
day 49 from three groups of animals: a single uninoculated pig, one pig
that had been inoculated once on day 0, and five pigs that were
inoculated three times on days 0, 14, and 28. Error bars illustrate
standard deviations. Data were subjected to an analysis of variance.
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The successful transfer of protection along with the transfer
of immune serum distinguishes our findings from similar ex-
periments performed with the temperature-dependent rabbit
model of chancroid (40). In the temperature-dependent rabbit
model, a single previous experimental infection with H. ducreyi
(26), immunization with cell wall components (26), a pilus
preparation (11, 12), or purified hemolysin (14) protected rab-
bits against future experimental challenge. However, passive
transfer of whole-cell H. ducreyi-specific or pilus-specific IgG
fractions did not confer protection (12). Passive transfer was
not successful despite the fact that passively immunized rabbits
displayed sustained, titratable antibody levels throughout the
experiment (12). Perhaps this result was due to the fact that
immune rabbit sera do not possess bactericidal activity against
H. ducreyi (20, 28).
The protection observed in the pig model may initially ap-
pear to contradict conclusions drawn from the human chal-
lenge model of chancroid. Previous experimental infection nei-
ther prohibits nor inhibits the development of a second
experimental infection in human volunteers (4, 49). However,
careful comparison of recovery data from the human and swine
models of chancroid revealed similarities. Human challenge
studies with a single infection reported that 57 to 100% of
lesion biopsies contain viable H. ducreyi (2, 3, 7, 8, 19, 39, 48,
50, 53, 54). In a human challenge reinfection study, viable H.
ducreyi was recovered from 83% of biopsies from previously
infected people and 67% of biopsies from individuals infected
for the first time (4). These percentages are consistent with the
percentages of culture-positive biopsies observed in pigs after
the first and second inoculations. Two and seven days after the
first inoculation, 100 and 89% of the swine biopsies were cul-
ture positive, respectively. All 20 of the biopsies collected 2
days after the second inoculation were positive, and 42% of the
biopsies collected 7 days after the second inoculation were also
culture positive. The significant drops in both the recovery and
the number of culture-positive lesions did not occur until after
the third inoculation.
It was concluded that experimental human infection to the
pustular stage of disease did not protect people against a sub-
sequent chancroid infection (4) because a naïve control group
and a group of individuals that had been previously experimen-
tally infected exhibited equivalent abilities to form both pus-
tules and papules. However, after a single previous inocula-
tion, pigs also developed papules and pustules in response to
inoculation with H. ducreyi. Pig lesion histology scores dropped
significantly only after the third inoculation (data not shown).
After the third inoculation, the average histology scores for the
PBS and live inoculations and the heat-killed bacteria inocu-
lations were virtually identical. While we saw the development
of protective immunity in the swine model of chancroid infec-
tion, the results from the first two rounds of pig inoculations
are similar to results from the human challenge model of
chancroid infection.
Pigs developed antibodies to H. ducreyi after single (29) and
repeated inoculations. In contrast, initial (38, 48) and repeated
(4) experimental human infection up to 14 days or the pustular
stage does not evoke an antibody response to bacterial proteins
or lipooligosaccharides. Unlike experimental infection, natu-
rally occurring chancroid results in the development of a hu-
moral response to H. ducreyi (1, 9, 10, 17, 36, 42, 47). Once
chancroid develops, the likelihood of producing H. ducreyi-
specific antibodies increases along with ulcer duration (10, 42).
Patients with genital ulcers persisting in excess of 4 weeks have
the strongest humoral response (10).
Antibodies may mediate protection through enhanced op-
sonization, increased bactericidal activity, blockage of attach-
ment, or some combination of all three effects. While people
with naturally occurring chancroid infection develop antibod-
ies against H. ducreyi, these antibodies are not bactericidal
(20). In contrast, antibodies produced by pigs that received
three inoculations were bactericidal against H. ducreyi, and
serum containing these antibodies conferred enhanced bacte-
rial clearance when transferred to naïve animals. This outcome
strongly suggested that the bactericidal ability of the H. du-
creyi-specific swine antibodies provided protection against
chancroid.
The development of bactericidal activity in pigs was specif-
ically dependent on the multiple inoculation protocol as the
uninoculated animal did not display enhanced bactericidal
ability and animals receiving single inoculations displayed only
transient increases in bactericidal activity. This greatly en-
hanced bactericidal activity was accomplished with only a five-
fold increase in H. ducreyi-specific antibody titer. While this
increase is not a large elevation in titer, protective antibody
titers following natural infections are often lower than the
titers seen postvaccination. For example, both previous natural
infection and vaccination against hepatitis B infection are pro-
tective, but after natural seroconversion, the average geomet-
ric mean titers of anti-hepatitis B antibodies are 41-fold lower
than titers at the peak of response in vaccinees (24).
We examined the longevity of the protection seen in the
three-times inoculated animals by inoculating a single pig from
this group a fourth time with H. ducreyi 70 days after the third
inoculation. While 25% of the lesions biopsied 2 days after the
fourth inoculation yielded live organisms, none of the lesions
biopsied 7 days after the fourth inoculation yielded live organ-
isms (data not shown). Reduced bacterial recovery once again
corresponded with increased bactericidal ability as 66  18%
FIG. 4. Average percentages of H. ducreyi-positive biopsies per pig
after passive transfer of immune or normal pig serum (NPS) to naïve
animals. Pigs were inoculated with H. ducreyi 1 day after infusion with
either NPS or immune serum. Lesion biopsies were collected either 2
or 7 days after inoculation. Entire lesion biopsies were minced and
plated for recovery. Bars represent the average percentage of culture-
positive biopsies per pig. Error bars represent standard errors of the
means. Analysis via t test revealed that while there was not a statisti-
cally significant difference in the percentage of culture-positive biop-
sies per pig on day 2, there was on day 7 (P  0.006).
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of H. ducreyi cells survived in serum drawn just prior to the
fourth inoculation, while only 15  4% of the cells survived in
serum drawn 7 days after the fourth inoculation (data not
shown). The rapid development of bactericidal activity sug-
gests the existence of antigen-specific memory B cells and
implies that memory B cell generation will be an important
component of any successful human H. ducreyi vaccine.
We have begun to identify targets of swine antibodies pro-
duced in response to repeated H. ducreyi exposure. All pigs
receiving repeated inoculations appear to develop antibodies
to the same distinct set of H. ducreyi antigens (data not shown).
We hope to identify both the specific antigens and their roles
as bactericidal antibody targets. The comparison of proteins
eliciting antibody responses could also be important in under-
standing how a humoral response is protective in pigs but not
in people.
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